Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects

Human Psychopharmacology

Volumn 25, Issue 5, 2010, Pages 404-409

  Si, Tianmei ^a   Shu, Liang ^a   Liu, Yi ^a   Su, Yun'Ai ^a   Guo, Chunmei ^a   Zhang, Hongyan ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

Author keywords

Chinese; Paliperidone ER; Pharmacokinetics; Tolerability

Indexed keywords

PALIPERIDONE; PLACEBO; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; GALACTORRHEA; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TIMED DRUG RELEASE; CHINA; DELAYED RELEASE FORMULATION; HALF LIFE TIME; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHINA; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; ISOXAZOLES; MALE; PYRIMIDINES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 77955727120     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1132     Document Type: Article

References (19)

1. Arakawa R, Ito H, Takano A, et al. 2008. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197: 229-235.
2. Ceskova E, Svestka J. 1993. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26: 121-124. (Pubitemid 23263240)
3. Davidson M, Emsley R, Kramer M, et al. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93: 117-130. (Pubitemid 46817944)
4. Fang J, Bourin M, Baker GB. 1999. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn Schmiederbergs Arch Pharmacol 359: 147-151. (Pubitemid 29142884)
5. Goff DC, Cather C, Evins AE, et al. 2005. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66: 183-194 quiz 47, 273-74.
6. hHwang TJ, Lee SM, Sun HJ, et al. 2003. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc 102: 30-36.
7. Kane J, Canas F, Kramer M, et al. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90: 147-161. (Pubitemid 46178537)
8. Karlsson P, Dencker E, Nyberg S, et al. 2005. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 15 (Suppl 3): S385.
9. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. 1995. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17: 402-12.
10. Marder SR, Kramer M, Ford L, et al. 2007. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62: 1363-1370. (Pubitemid 350180724)
11. Masand PS, Narasimhan M. 2006. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 1: 47-56.
12. Moller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C. 1998. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 13: 99-106. (Pubitemid 28318347)
13. Owen RT. 2007. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc) 43: 249-258.
14. Owens DG. 1994. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55: Suppl: 29-35. (Pubitemid 24179367)
15. Peuskens J. 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166: 712-726 discussion 27-33.
16. Spina E, Avenoso A, Salemi GFM, Scordo MG, Madia MAAG, Perucca E. 2001. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153: 238-243. (Pubitemid 32127893)
17. Vermeir M, Naessens I, Remmerie B, et al. 2008. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36: 769-779. (Pubitemid 351468385)
18. Weiden PJ, Olfson M. 1995. Cost of relapse in schizophrenia. Schizophr Bull 21: 419-429.
19. Zhou ZL, Li X, Peng HY, et al. 2006. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 27: 381-386. (Pubitemid 43357037)